ScripSpexis AG , the Swiss biotech that was only created at the end of last year through the merger of troubled Polyphor AG and EnBiotix , is already facing an uncertain future as it battles for funds t
ScripItaly’s Zambon Co. SPA has paid an initial €140m to acquire the VC-backed German/US biotech, Breath Therapeutics Holding BV in a move that strengthens the specialty products pipeline of the mid-si
HBW InsightPari launches first OTC cough and cold range Representing its first foray into the German cough and cold market, Pari's ectoine-based range of cold remedies leverage the firm’s 100 years of experience
Generics BulletinIt's hard to keep the US regulatory and approval news brief this week: The Center for Drug Evaluation and Research’s novel agent approvals count for 2018 reached 41 with the approval of three new onco